Prevalence of primary resistance at baseline in acutely and recently infected subjects enrolled in AIDS clinical trials group protocol 371
- PMID: 20733405
- PMCID: PMC2928582
- DOI: 10.1097/QAI.0b013e3181d5a800
Prevalence of primary resistance at baseline in acutely and recently infected subjects enrolled in AIDS clinical trials group protocol 371
References
-
- Booth CL, Geretti AM. Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection. J Antimicrob Chemother. 2007 Jun;59(6):1047–1056. - PubMed
-
- Jain V, Susupira C, Deeks S, et al. Persistence of Transmitted Drug-resistance Mutations in Patients with Acute HIV. 16th Conference on Retroviruses and Opportunistic Infections; Montreal, Canada. 2009.
-
- Wainberg MA. The impact of the M184V substitution on drug resistance and viral fitness. Expert Review of Antiinfective Therapy. 2004;2(1):147–151. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- U01 AI069502/AI/NIAID NIH HHS/United States
- AI-68634/AI/NIAID NIH HHS/United States
- U01AI-69450/AI/NIAID NIH HHS/United States
- UM1 AI068634/AI/NIAID NIH HHS/United States
- AI-68636/AI/NIAID NIH HHS/United States
- U01 AI069450/AI/NIAID NIH HHS/United States
- AI-69450/AI/NIAID NIH HHS/United States
- U01 AI-69511/AI/NIAID NIH HHS/United States
- P30 AI027763/AI/NIAID NIH HHS/United States
- U01 AI069511/AI/NIAID NIH HHS/United States
- UM1 AI069450/AI/NIAID NIH HHS/United States
- P30 AI-027763/AI/NIAID NIH HHS/United States
- U01 AI038858/AI/NIAID NIH HHS/United States
- U01 AI068636/AI/NIAID NIH HHS/United States
- AI-38885/AI/NIAID NIH HHS/United States
- U01 AI-069502/AI/NIAID NIH HHS/United States
- AI-38858/AI/NIAID NIH HHS/United States
- P30 AI078498/AI/NIAID NIH HHS/United States
- P30 AI-078498/AI/NIAID NIH HHS/United States
- U01 AI068634/AI/NIAID NIH HHS/United States
- UM1 AI068636/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
